Press Release

Rheumatoid Arthritis Market Report 2017-2030: The market is Expected to Grow at a CAGR of 3%, Estimates DelveInsight

Rheumatoid Arthritis Market Report 2017-2030: The market is Expected to Grow at a CAGR of approx. 3%, Estimates DelveInsight

 DelveInsight’s Rheumatoid Arthritis Market Insights Report offers a detailed analysis of Disease, its causes, symptoms, diagnostics modalities and treatment options. 

The report also offers comprehensive insights into Rheumatoid Arthritis market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing Rheumatoid Arthritis clinical trials, collaboration in the space, and key pharmaceutical companies actively pushing the growth of Rheumatoid Arthritis market size forward in the 7MM (the US, EU5 (the UK, Germany, Spain, France and Italy), and Japan).

Some of the key highlights from the Rheumatoid Arthritis Market Insights: 

  • The total prevalent cases of RA was found to be 4,356,793 cases in 2017 in the 7MM, which are anticipated to increase during the study period, i.e., 2017–30. 
  • In 2017, the US accounted for the maximum Rheumatoid Arthritis prevalent cases, which are expected to increase during the study period of 2017–30.
  • AbbVie’s JAK inhibitor Rinvoq (upadacitinib) is one of the major contenders among this drug class for RA. This candidate has shown strong efficacy, including the superiority of Humira. However, Rinvoq approved with a label warning serious infections, malignancy, and thrombosis like older JAK inhibitors Xeljanz (tofacitinib) and Olumiant (baricitnib). 

Learn more by requesting for sample @ Rheumatoid Arthritis Market Landscape 

Rheumatoid Arthritis Overview:

Rheumatoid arthritis is a chronic inflammatory or autoimmune disease which is known to affect the joints of the body adversely. An autoimmune disorder is a condition where the immunity system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harm the joints. Even after years of research, the cause of rheumatoid arthritis is still unknown. 

Rheumatoid Arthritis is found to be more common in women than men.

Rheumatoid Arthritis Symptoms:

Symptoms include joint pain, stiffness, swelling, and decreased movement of the joints. 

Rheumatoid Arthritis Diagnosis:

Diagnosis is made by a combination of the patient’s symptoms, assessment of risk factors, results of doctor’s examination, family history, a joint assessment by ultrasound sonography, & assessment of laboratory markers.

For more insights into Disease, causes and treatment, reach out @ Rheumatoid Arthritis Treatment Landscape. 

Rheumatoid Arthritis Epidemiology Segmentation 

The Rheumatoid Arthritis Market report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

  • Rheumatoid Arthritis Prevalence 
  • Severity Specific Rheumatoid Arthritis Prevalence 
  • Diagnosed and Treatable Cases of Rheumatoid Arthritis

Visit for more @Rheumatoid Arthritis Epidemiological Insights. 

 

Rheumatoid Arthritis Pipeline Therapies and Key Companies 

  •  Otilimab/GSK3196165 (GlaxoSmithKline)
  •  Olokizumab (R Pharm)
  •  Filgotinib (Gilead and Galapagos NV)
  •  Ozoralizumab/TS-152 (Taisho Pharmaceuticals/Ablynx)
  •  VIB4920 (Viela Bio)
  •  ATI-450/CDD-450 (Aclaris Therapeutics)
  •  ABBV-3373 and ABBV-154 (AbbVie)
  •  Branebrutinib (Bristol Myers Squibb)
  •  JTE-051 (Akros Pharma/Japan Tobacco)
  •  MPC-300-IV/ Allogeneic Mesenchymal Precursor Cells (Mesoblast)
  •  Dekavil/F8IL10 (Pfizer/Philogen)
  •  PF-06651600/Ritlecitinib (Pfizer)
  •  Evobrutinib/M2951 (Merck)
  •  PF-06650833 (Pfizer)
  •  Fenebrutinib/GDC-0853/RG7845 (Roche/Genentech)
  •  Bimekizumab (UCB Pharma/PRA HEALTH SCIENCES)
  •  Namilumab/IZN-101/AMG203 (Izana Bioscience/Takeda)
  •  MPC-300-IV/ Allogeneic Mesenchymal Precursor Cells (Mesoblast)
  •  ABX464 (Abivax)
  • SKI-O-703 (Genosco/Oscotec)
  • HB-AdMSCs (Hope Biosciences)

For more information, visit Rheumatoid Arthritis Market Analysis, Patient Pool and Emerging Therapies.

Rheumatoid Arthritis Market Drivers:

  • Increase in the prevalence population of RA
  • Increase in the geriatric population
  • Rich Emerging Pipeline
  • And Many Others

Scope of the Report

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Rheumatoid Arthritis, covering causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight into Rheumatoid Arthritis epidemiology and treatment in the 7MM
  • Current and emerging therapies for Rheumatoid Arthritis
  • Rheumatoid Arthritis market drivers and barriers 

Get in touch with our Business executive @ Rheumatoid Arthritis Market Landscape Analysis.

Table of Contents 

1 Key Insights
2 Report Introduction
3 Competitive Intelligence Analysis for Rheumatoid Arthritis
4 Rheumatoid Arthritis Market Overview at a Glance
5 Executive Summary of Rheumatoid Arthritis
6 Rheumatoid Arthritis Epidemiology and Market Methodology
7 Rheumatoid Arthritis Epidemiology and Patient Population
8 Rheumatoid Arthritis Patient Journey
9 Treatment Algorithm, Current Treatment, and Medical Practices
10 Key Endpoints in Rheumatoid Arthritis Clinical Trials
11 Rheumatoid Arthritis Marketed Therapies
12 Rheumatoid Arthritis Emerging Therapies
13 Rheumatoid Arthritis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Rheumatoid Arthritis
16 KOL Reviews
17 Case Reports
18 Rheumatoid Arthritis Market Drivers
19 Rheumatoid Arthritis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight

Learn more about the report offerings @ Rheumatoid Arthritis Market Outlook

Related Reports 

Gouty Arthritis Market

DelveInsight’s ‘Gouty Arthritis Market Insights, Epidemiology and Market Forecast 2030’ report will provide Gouty Arthritis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Dyve Biosciences, Selecta Biosciences, LG Chem, Horizon Therapeutics, Shanton Pharma and several others. 

Juvenile Rheumatoid Arthritis Market

DelveInsight’s “Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2030” report.

Juvenile Idiopathic Arthritis Market

DelveInsight’s “Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast-2030” report will provide Juvenile Idiopathic Arthritis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as AbbVie, Amgen, Bristol-Myers Squibb, Genentech, Janssen, Novartis, Pfizer, Regeneron, Roche, Sanofi, Sobi, UCB and several others.

Psoriatic Arthritis Market

DelveInsight’s ‘Psoriatic Arthritis Market Insights, Epidemiology and Market Forecast – 2030’ report will provide Psoriatic Arthritis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as UCB Biopharma, AbbVie, Bristol-Myers Squibb, Sun Pharma and several others.

Reactive Arthritis Market

DelveInsight’s “Reactive Arthritis Market Insights, Epidemiology, and Market Forecast-2030” report. 

Giant Cell Arteritis Market

DelveInsight’s “Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2030” report will provide Psoriatic Arthritis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Regeneron Pharmaceuticals, Novartis Pharmaceuticals, AbbVie and several others

About DelveInsight 

DelveInsight is a leading Market Research, and Business Consultant focused purely on life sciences. It assists pharma companies by providing them with end-to-end solutions to boost their performance.

Get access to all the Pharma and healthcare market research reports through our market research subscription-based platform PharmDelve.

Connect With Us at:

 LinkedIn | Facebook | Twitter

Contact Information:

Ankit Nigam
[email protected] 
+1(919)321-6187 

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *